Skip to content

Person-checked company records fromPerson-checked records $750See a worked exampleHuman review in progress

Talk to sales

KeptIndex

Acadia Pharmaceuticals Inc.

Initiate the bunionectomy Phase 2 study of ACP-044 for acute pain

Delivered by the deadline

AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.

Announced
24 Feb 2021
Due
31 Mar 2021
Delivered
March 2021
  • Deadline
  • Met
  • Late
  • Not met
  • Today

What the company said

“A bunionectomy study is expected to initiate in the first quarter of 2021 and an osteoarthritis study is expected to initiate in the second quarter of 2021.”

What we found

Evidence strength A What the grades mean

The company's later filings say the bunionectomy Phase 2 study of ACP-044 was initiated in March 2021, within the first-quarter 2021 deadline.

  • A
    Acadia Pharmaceuticals Inc. 10-Q filed 2021-05-06 Regulatory filing · published 6 May 2021 · retrieved 26 Oct 2026 · kept permanently by the SEC · fingerprint 453843f3a5aa
    “In March, 2021 we initiated a Phase 2 study evaluating ACP-044 for the treatment of postoperative pain following bunionectomy surgery.” ✓ confirmed on the page
  • A
    Acadia Pharmaceuticals Inc. 10-Q filed 2021-08-05 Regulatory filing · published 5 Aug 2021 · retrieved 26 Oct 2026 · kept permanently by the SEC · fingerprint ac673b3c83d1
    “In March 2021, we initiated a Phase 2 study evaluating ACP-044 for the treatment of postoperative pain following bunionectomy surgery.” ✓ confirmed on the page

Checked 26 Oct 2026.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type
Clinical milestone
Indicative materiality
Medium rules
Action
Initiate
Deliverable
Bunionectomy Phase 2 study of ACP-044
Language
Expected (“expects”, “plans”)
In the company’s control
High
Specificity
High

How this entry was checked

  1. Commitment recordedThe company's words were matched word for word against the filing.
  2. First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.

Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works

Are you Acadia Pharmaceuticals Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2021-ACAD-024372 · Corrections policy

The Deadline Report

One email a week: the corporate commitments that came due, which were met, which slipped, and what is due next. Free. Stop any time.

No advertising. We never sell or share your address.